The Prostate

Cover image for Vol. 71 Issue 12

September 2011

Volume 71, Issue 12

Pages 1251–1366

  1. Original Articles

    1. Top of page
    2. Original Articles
    1. Development of a brain metastatic canine prostate cancer cell line (pages 1251–1263)

      Nanda K. Thudi, Sherry T. Shu, Chelsea K. Martin, Lisa G. Lanigan, Murali V.P. Nadella, Adrie Van Bokhoven, Jillian L. Werbeck, Jessica K. Simmons, Sridhar Murahari, William C. Kisseberth, Matthew Breen, Christina Williams, Ching-Shih Chen, Laurie K. McCauley, Evan T. Keller and Thomas J. Rosol

      Version of Record online: 14 FEB 2011 | DOI: 10.1002/pros.21341

    2. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (pages 1264–1275)

      Donald L. Trump, Heather Payne, Kurt Miller, Johann S. de Bono, Joe Stephenson III, Howard A. Burris III, Faith Nathan, Maria Taboada, Thomas Morris and Andreas Hubner

      Version of Record online: 26 JAN 2011 | DOI: 10.1002/pros.21342

    3. Increased cancer cell proliferation in prostate cancer patients with high levels of serum folate (pages 1287–1293)

      Jeffrey J. Tomaszewski, Jessica L. Cummings, Anil V. Parwani, Rajiv Dhir, Joel B. Mason, Joel B. Nelson, Dean J. Bacich and Denise S. O'Keefe

      Version of Record online: 9 FEB 2011 | DOI: 10.1002/pros.21346

    4. Distribution of the lymphatic vessels in the prostatic fascia (pages 1294–1298)

      Hideo Soga, Atsushi Takenaka, Gen Murakami, Takahiro Haraguchi, Hideaki Miyake, Kazushi Tanaka and Masato Fujisawa

      Version of Record online: 9 FEB 2011 | DOI: 10.1002/pros.21343

    5. Androgen receptor regulates expression of the MUC1-C oncoprotein in human prostate cancer cells (pages 1299–1308)

      Hasan Rajabi, Maya Datt Joshi, Caining Jin, Rehan Ahmad and Donald Kufe

      Version of Record online: 9 FEB 2011 | DOI: 10.1002/pros.21344

    6. High-dose-rate brachytherapy boost to the dominant intra-prostatic tumor region: Hemi-irradiation of prostate cancer (pages 1309–1316)

      Ulrike Schick, Youri Popowski, Philippe Nouet, Sabine Bieri, Michel Rouzaud, Haleem Khan, Damien Charles Weber and Raymond Miralbell

      Version of Record online: 9 FEB 2011 | DOI: 10.1002/pros.21347

    7. Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy (pages 1317–1324)

      Yinong Niu, Rongbin Ge, Libing Hu, Christian Diaz, Zongwei Wang, Chin-Lee Wu and Aria F. Olumi

      Version of Record online: 9 FEB 2011 | DOI: 10.1002/pros.21348

    8. Risk factors for incidental prostate cancer—who should not undergo vaporization of the prostate for benign prostate hyperplasia? (pages 1325–1331)

      Susan Voigt, Friederike Hüttig, Rainer Koch, Stefan Propping, Catharina Propping, Marc-Oliver Grimm and Manfred Wirth

      Version of Record online: 9 FEB 2011 | DOI: 10.1002/pros.21349

    9. TGF-β1-induced EMT of non-transformed prostate hyperplasia cells is characterized by early induction of SNAI2/Slug (pages 1332–1343)

      Eva Slabáková, Zuzana Pernicová, Eva Slavíčková, Andrea Staršíchová, Alois Kozubík and Karel Souček

      Version of Record online: 14 FEB 2011 | DOI: 10.1002/pros.21350

    10. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: Optimization from lead compound to CH5137291 (pages 1344–1356)

      Hiromitsu Kawata, Shinichi Arai, Toshito Nakagawa, Nobuyuki Ishikura, Ayako Nishimoto, Hitoshi Yoshino, Takuya Shiraishi, Kazutaka Tachibana, Ryo Nakamura and Haruhiko Sato

      Version of Record online: 9 FEB 2011 | DOI: 10.1002/pros.21351